Last updated: February 19, 2026
What is the current market landscape for brivaracetam?
Brivaracetam (brand name: Briviact) is an antiepileptic drug (AED) used primarily to treat partial-onset seizures in adults with epilepsy. It was approved by the U.S. Food and Drug Administration (FDA) in 2016 and the European Medicines Agency (EMA) in 2017. Global sales reached approximately $400 million in 2022, with growth driven by expanding indications and geographic penetration.
Major competitors include levetiracetam (market leader), lacosamide, and perampanel. Brivaracetam’s differentiator is its higher affinity for synaptic vesicle protein 2A (SV2A), which improves tolerability and efficacy in certain patient groups.
How have regulatory decisions influenced market entry?
FDA and EMA approvals
- 2016 (FDA): Approved for adjunctive treatment of partial seizures in adults.
- 2017 (EMA): Approved for similar indications across Europe.
Expansions and new indications
- 2018: Post-approval studies on pediatric populations.
- 2020: Filing for monotherapy approval in the U.S. and Europe; approvals pending as of 2023.
Regional authorization status
| Region |
Approval Status |
Notes |
| North America |
Approved (2016) |
For adjunctive partial seizures. |
| Europe |
Approved (2017) |
For adjunctive partial seizures. |
| Asia-Pacific |
Approved in Japan (2019) |
For adjunctive treatment. |
| Rest of world |
Pending approvals or under review |
Limited market access in emerging markets. |
What are the key market drivers and barriers?
Market Drivers
- Growing epilepsy prevalence: About 50 million globally, increasing demand for effective treatments.
- Expanding indications: Ongoing clinical trials for monotherapy, generalized seizures, and pediatric use.
- Enhanced safety profile: Better tolerability compared to phenobarbital and phenytoin.
- Favorable dosing regimen: Once or twice daily dosing improves patient adherence.
Market Barriers
- High generic penetration: Levetiracetam accounts for over 70% of the epilepsy AED market, constraining growth for branded alternatives.
- Pricing pressures: Payors favor lower-cost generics, limiting revenue growth.
- Limited awareness outside specialist centers: Usage confined to neurologists and epileptologists, slowing adoption.
How does the financial trajectory look?
Revenue evolution
| Year |
Estimated Global Sales |
Growth Rate (YoY) |
Key Factors |
| 2016 |
$20 million |
— |
Launch year |
| 2018 |
$180 million |
80% |
Market expansion, broader insurance coverage |
| 2020 |
$330 million |
83% |
Indication expansion, European uptake |
| 2022 |
$400 million |
21% |
Saturation in core markets, emerging markets gaining access |
R&D expenditure
- Estimated $150 million since 2010, primarily for Phase III trials, registration, and post-marketing studies.
- Ongoing R&D initiatives include clinical trials for monotherapy and other epilepsy types, with projected investments of $50 million over three years.
Market projections
- Compound annual growth rate (CAGR) from 2022 to 2027: approximately 7%
- Forecasted revenue in 2027: $620 million, driven by expanded indications and geographic expansion.
Which factors influence future growth potential?
- Pipeline developments: Ongoing Phase III trials for generalized and pediatric epilepsy. Successful outcomes could unlock new revenue streams.
- Regulatory approvals: Pending approval for monotherapy and broader indications in major markets.
- Pricing negotiations: Managed entry prices in emerging markets could boost volume.
- Market competition: New entrants with novel mechanisms may challenge brivaracetam’s market position.
What are the key risks to financial forecasts?
- Generic erosion: Entry of levetiracetam generics reduces pricing power.
- Regulatory hurdles: Delays or refusals for new indications affect revenue growth.
- Market acceptance: Preference for established therapies may slow growth.
- Manufacturing interruptions: Supply chain disruptions could impact availability.
Summary table of market projections
| Year |
Estimated Revenue (USD million) |
Growth Rate |
Drivers/Constraints |
| 2023 |
$420 |
5% |
Early commercial stability, competition remains tight |
| 2025 |
$520 |
6% |
Broader indications, emerging markets |
| 2027 |
$620 |
7% |
Continued pipeline success, increasing adoption |
Key Takeaways
- Brivaracetam remains a niche but growing AED with broad potential driven by pipeline progress.
- Competition from levetiracetam and generics constrains pricing, though safety and efficacy advantages support uptake.
- Regulatory milestones, especially regarding monotherapy approval, are pivotal to expanding revenue streams.
- Geographic expansion into emerging markets could significantly influence long-term growth.
- Market risks include regulatory delays, price erosion, and competition from novel treatments.
FAQs
1. What are the main clinical benefits of brivaracetam?
It offers a higher affinity for SV2A, leading to improved tolerability and efficacy in controlling partial seizures over some existing AEDs.
2. How does brivaracetam’s regulatory status impact its market potential?
FDA and EMA approvals enable access in major markets, but pending approvals for monotherapy and broader indications limit revenue at present.
3. What competitive advantages does brivaracetam hold?
A better safety profile, convenient dosing schedules, and clinical data supporting efficacy in difficult-to-treat subpopulations.
4. Which markets are likely to drive the most growth?
North America and Europe remain mature but highly competitive markets. Asia-Pacific, especially Japan and emerging markets, present substantial growth opportunities.
5. How vulnerable is brivaracetam to generic competition?
Highly; levetiracetam's dominance and low-cost generics compress margins. Value differentiation depends on safety, specific indications, and geographic coverage.
References
[1] FDA. (2016). FDA approves Briviact to treat partial seizures. U.S. Food and Drug Administration.
[2] EMA. (2017). European Medicines Agency approval of Briviact.
[3] MarketResearch.com. (2023). Global epilepsy market report.
[4] IQVIA. (2022). Top-selling epilepsy drugs.
[5] ClinicalTrials.gov. (2023). Brivaracetam clinical trials.
